DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 19-735/S-058

Ortho-McNeil Pharmaceutical, Inc.
c/o Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
ATTN: Ms. Alysia Baldwin-Ferro
Senior Director, Regulatory Affairs
920 U.S. Highway 202, P.O. Box 300
Raritan, NJ 08869-0602

Dear Ms. Baldwin-Ferro:

Please refer to your supplemental new drug application, dated and received on November 9, 2007, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for the following:

NDA Number	Supplement Number	Drug Product
19-735	058	Floxin® (ofloxacin) Tablets, 200 mg, 300 mg, and 400 mg

We also acknowledge receipt of your submission dated November 15, 2007.

This "Special Supplement - Changes Being Effected" supplemental application proposes revising the content of labeling for the package insert to ensure consistency in the communication of the risk of phototoxicity associated with the use of fluoroquinolones, including ofloxacin.

We have completed our review of this application. This application is approved, effective on the date of this letter, for use as recommended in the final printed labeling (FPL) submitted on November 15, 2007 with the minor editorial revisions listed below (~~strikethrough~~ = deleted and double-underline = added):

1. The **PRECAUTIONS**/**General** subsection was modified as follows:

   Moderate to severe photosensitivity/phototoxicity reactions, the latter of which may manifest as exaggerated sunburn reactions (e.g., burning, erythema, exudation, vesicles, blistering, edema) involving areas exposed to light (typically the face, "V" area of the neck, extensor surfaces of the forearms, dorsa of the hands), can be associated with the use of quinolones after sun or UV light exposure. Therefore, excessive exposure to these sources of light should be avoided. Drug therapy should be discontinued if photosensitivity/phototoxicity occurs (See **ADVERSE REACTIONS/Post-Marketing Adverse Events**).

2. In the **"Patient Information About Floxin®"/** "**What are possible side effects of Floxin?"** the following paragraph was modified as follows:

   Sun sensitivity (photosensitivity), which can appear as skin eruption or severe sunburn can occur in some patients taking quinolones ~~antibiotics~~ after exposure to sunlight or artificial ultraviolet light (UV) (e.g. tanning beds). Floxin® has been infrequently associated with photosensitivity. Avoid excessive exposure to sunlight or artificial UV light while taking Floxin®. Use a sunscreen and wear protective clothing if out in the sun. If photosensitivity develops, contact your physician.

The overall revisions to the package insert were as follows (~~strikethrough~~ = deleted and double-underline = added):

1. The **PRECAUTIONS**/**General** subsection was modified as follows:

   ~~Moderate to severe phototoxicity reactions have been observed in patients exposed to direct sunlight while receiving some drugs in this class, including ofloxacin. Excessive sunlight should be avoided. Therapy should be discontinued if phototoxicity (e.g., a skin eruption) occurs.~~ Moderate to severe photosensitivity/phototoxicity reactions, the latter of which may manifest as exaggerated sunburn reactions (e.g., burning, erythema, exudation, vesicles, blistering, edema) involving areas exposed to light (typically the face, "V" area of the neck, extensor surfaces of the forearms, dorsa of the hands), can be associated with the use of quinolones after sun or UV light exposure. Therefore, excessive exposure to these sources of light should be avoided. Drug therapy should be discontinued if photosensitivity/phototoxicity occurs (See **ADVERSE REACTIONS/Post-Marketing Adverse Events**).

2. The **PRECAUTIONS**/**Information for Patients** subsection was modified as follows:

   - ~~to avoid excessive sunlight or artificial ultraviolet (UV) light while receiving ofloxacin and to discontinue therapy if phototoxicity occurs.~~ that photosensitivity/phototoxicity has been reported in patients receiving quinolone antibiotics. Patients should minimize or avoid exposure to natural or artificial sunlight (tanning beds or UVA/B treatment) while taking quinolones. If patients need to be outdoors while using quinolones, they should wear loose-fitting clothes that protect skin from sun exposure and discuss other sun protection measures with their physician. If a sunburn-like reaction or skin eruption occurs, patients should contact their physician;

3. In the **ADVERSE REACTIONS/Post-Marketing Adverse Events s**ection, the following was modified:

   Additional adverse events, regardless of relationship to drug, reported from worldwide marketing experience with quinolones, including ofloxacin:

   Skin/Hypersensitivity: anaphylactic (-toid) reactions/shock; purpura, serum sickness, erythema multiforme/Stevens-Johnson Syndrome, erythema nodosum, exfliative dermatitis, hyperpigmentation, toxic epidermal necrolysis, conjunctivitis, photosensitivity/phototoxicity reaction, vesiculobullous eruption (See **WARNINGS** and **PRECAUTIONS**).

4. In the **"Patient Information About Floxin®"/ "What are possible side effects of Floxin?"** the following paragraph was modified as follows:

   ~~Some quinolone antibiotics have been associated with the development of phototoxicity ("sunburns" and "blistering sunburns") following exposure to sunlight or other sources of ultraviolet light such as artificial ultraviolet light used in tanning salons. Floxin® has been infrequently associated with phototoxicity. You should avoid excessive exposure to sunlight or artificial ultraviolet light while you are taking Floxin®.~~ Sun sensitivity (photosensitivity), which can appear as skin eruption or severe sunburn can occur in some patients taking quinolones after exposure to sunlight or artificial ultraviolet light (UV) (e.g. tanning beds). Floxin® has been infrequently associated with photosensitivity. Avoid excessive exposure to sunlight or artificial UV light while taking Floxin®. Use a sunscreen and wear protective clothing if out in the sun. If photosensitivity develops, contact your physician.

5. Minor editorial changes throughout the labeling.

LETTERS TO HEALTH CARE PROFESSIONALS

If you issue a letter communicating important information about these drug products (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to these NDAs and a copy to the following address:

MEDWATCH
Food and Drug Administration
5515 Security Lane
HFD-001, Suite 5100
Rockville, MD 20852

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Rebecca D. Saville, Pharm.D., Regulatory Project Manager, at (301) 796-1600.

Sincerely,

{See appended electronic signature page}

Renata Albrecht, M.D.
Director
Division of Special Pathogen and Transplant Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research

Enclosure

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Renata Albrecht

12/13/2007 08:39:15 PM